Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Tumor markers--how they should be applied].

P Stieber1, V Heinemann, A Schalhorn

  • 1Institut für Klinische Chemie, Klinikum der Universität München--Grosshadern. Petra.Stieber@med.uni-muenchen.de

MMW Fortschritte Der Medizin
|June 17, 2005
PubMed
Summary

Tumor marker testing is not ideal for general screening but is crucial for specific cancers like germ cell tumors. Monitoring tumor marker kinetics against individual baselines is vital for disease management and follow-up.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP trial (AIO-PAK-0113).

ESMO gastrointestinal oncology·2026
Same author

Risk of disease progression in first-line metastatic colorectal cancer therapy to guide disease reassessments-analysis of 11 trials by AIO and GONO.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Corrigendum to "Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)": [ESMO Open 7 (2024) 100552].

ESMO open·2024
Same author

Translating efficacy of liver transplantation in liver-limited metastatic colorectal cancer into clinical practice: the TransMet trial.

ESMO open·2024
Same author

Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI.

ESMO open·2024
Same author

Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial.

ESMO open·2024

Area of Science:

  • Oncology
  • Clinical Chemistry

Context:

  • Tumor markers are biochemical indicators of cancer.
  • Current screening methods have limitations, with few exceptions like PSA and thyroglobulin.

Purpose:

  • To evaluate the utility of tumor marker determination in cancer diagnosis, surgical planning, and post-treatment monitoring.
  • To emphasize the importance of kinetic analysis of tumor markers for disease management.

Summary:

  • Tumor marker testing is generally unsuitable for cancer screening, except for specific markers like prostate-specific antigen (PSA) and thyroglobulin.
  • Tumor marker levels are valuable for surgical planning, especially in germ cell tumors, and essential for establishing a baseline post-treatment.
  • Monitoring the dynamic changes (kinetics) of tumor markers relative to individual baseline values is critical for assessing disease progression and guiding follow-up care.

Related Experiment Videos

Impact:

  • Highlights the specific roles of tumor markers beyond screening, focusing on surgical and post-therapeutic monitoring.
  • Stresses the necessity of consistent assay methodology for accurate interpretation of serial tumor marker measurements.
  • Informs clinical practice regarding the appropriate application and interpretation of tumor marker data in cancer patient management.